Soligenix

Soligenix Profit per Employee

The Profit per Employee of Soligenix (SNGX) as of Oct 17, 2026 is -852,336.92 USD. In the previous year, Profit per Employee was -635,890.46 USD — a change of 34.04% (lower).

Profit per Employee

-852,336.92USD

YoY

34.04%

Last updated:

Profit per Employee of Soligenix is 2025 -852,336.92 USD. Profit per Employee of Soligenix was 2024 -635,890.46 USD. It decreases by 34.04% lower compared to the previous year.

The Soligenix Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2018
-684,615.38 USD
Jan 1, 2019
-719,660.92 USD
Jan 1, 2020
-1.36 M USD
Jan 1, 2021
-965,459.46 USD
Jan 1, 2022
-1.06 M USD
Jan 1, 2023
-472,363.85 USD
Jan 1, 2024
-635,890.46 USD
Jan 1, 2025
-852,336.92 USD
The Soligenix Profit per Employee history
YEARProfit per EmployeeYoY
-852,336.92USD+34.04%
-635,890.46USD+34.62%
-472,363.85USD-55.50%
-1.06 MUSD+9.94%
-965,459.46USD-29.04%
-1.36 MUSD+89.07%
-719,660.92USD+5.12%
-684,615.38USD+24.53%
-549,769.23USD+120.25%
-249,615.38USD-58.56%
-602,384.62USD+16.76%
-515,923.08USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Profit per Employee of Soligenix is -852,336.92 USD in 2025.

Profit per Employee of Soligenix changed from -635,890.46 USD to -852,336.92 USD, representing a 34.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee Soligenix since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's Soligenix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Soligenix

All Key Metrics — Soligenix